Source: LifesiteNews.com
Norway joins Finland, Sweden, and the UK in denouncing puberty blockers, cross-sex hormones, and ‘sex changes’ surgeries for minors confused about their gender.
The Norwegian Healthcare Investigation Board (NHIB) is the latest European body to announce that the so-called “affirmative model of care” for gender dysphoric minors is not supported by evidence and is advising against the use of cross-sex hormones, puberty blockers, and “sex change” surgeries for minors. The NHIB recommended that these “treatments” be classified as experimental and noted that the spike in children identifying as transgender is concerning. “The knowledge base, especially research-based knowledge, for gender confirmation treatment (hormonal and surgical) is insufficient,” the report notes. “Little is known about the long-term effects.” Instead, the NHIB recommends that more data — especially follow-up data — be collected and noted that the current standards endanger children, who cannot consent to the irreversible impacts of these treatments. Media reports indicate that the new recommendations come after families complained about “safety, lack of parental involvement, and lack of follow up for underage patients.”